Analysts Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $29.00

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given an average rating of “Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $29.00.

IMNM has been the subject of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Tuesday, August 13th. Piper Sandler dropped their target price on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th.

Insider Buying and Selling at Immunome

In other Immunome news, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Immunome news, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the transaction, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at $760,090.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in Immunome in the second quarter worth approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Immunome during the 2nd quarter worth $97,000. Arizona State Retirement System boosted its stake in shares of Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after acquiring an additional 918 shares during the last quarter. EntryPoint Capital LLC boosted its stake in shares of Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after acquiring an additional 5,466 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Stock Up 3.0 %

NASDAQ IMNM opened at $12.23 on Monday. The company has a 50-day simple moving average of $14.14 and a two-hundred day simple moving average of $15.04. Immunome has a 12-month low of $6.93 and a 12-month high of $30.96. The firm has a market cap of $734.41 million, a price-to-earnings ratio of -1.59 and a beta of 1.76.

Immunome (NASDAQ:IMNM) last posted its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The firm had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. Equities analysts expect that Immunome will post -1.92 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.